Both clinical trials NCT03524365 (BRAVES) and NCT04677101 (LIBRA) tested perilipin-2 (PLIN2) and a member of RAS oncogene family (RAB14) in circulating monocytes as a prognosticator of histological NASH and liver fibrosis, respectively. Here, PLIN2 is linked to metabolic dysfunction-associated steatohepatitis.